Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Lysine-specific post-translational modifications of proteins in the life cycle of viruses.

Loboda AP, Soond SM, Piacentini M, Barlev NA.

Cell Cycle. 2019 Sep;18(17):1995-2005. doi: 10.1080/15384101.2019.1639305. Epub 2019 Jul 10.

PMID:
31291816
2.

Autophagy suppresses the pathogenic immune response to dietary antigens in cystic fibrosis.

Villella VR, Esposito S, Ferrari E, Monzani R, Tosco A, Rossin F, Castaldo A, Silano M, Marseglia GL, Romani L, Barlev NA, Piacentini M, Raia V, Kroemer G, Maiuri L.

Cell Death Dis. 2019 Mar 15;10(4):258. doi: 10.1038/s41419-019-1500-x.

3.

Isatin-Schiff base-copper (II) complex induces cell death in p53-positive tumors.

Bulatov E, Sayarova R, Mingaleeva R, Miftakhova R, Gomzikova M, Ignatyev Y, Petukhov A, Davidovich P, Rizvanov A, Barlev NA.

Cell Death Discov. 2018 Nov 13;4:103. doi: 10.1038/s41420-018-0120-z. eCollection 2018.

4.

Orphan receptor NR4A3 is a novel target of p53 that contributes to apoptosis.

Fedorova O, Petukhov A, Daks A, Shuvalov O, Leonova T, Vasileva E, Aksenov N, Melino G, Barlev NA.

Oncogene. 2019 Mar;38(12):2108-2122. doi: 10.1038/s41388-018-0566-8. Epub 2018 Nov 19.

PMID:
30455429
5.

EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer.

Tulchinsky E, Demidov O, Kriajevska M, Barlev NA, Imyanitov E.

Biochim Biophys Acta Rev Cancer. 2019 Jan;1871(1):29-39. doi: 10.1016/j.bbcan.2018.10.003. Epub 2018 Nov 10. Review.

PMID:
30419315
6.

Erratum: Actin-binding protein alpha-actinin 4 (ACTN4) is a transcriptional co-activator of RelA/p65 sub-unit of NF-kB.

Aksenova V, Turoverova L, Khotin M, Magnusson KE, Tulchinsky E, Melino G, Pinaev GP, Barlev N, Tentler D.

Oncotarget. 2018 Sep 28;9(76):34450. doi: 10.18632/oncotarget.26206. eCollection 2018 Sep 28.

7.

BTK: a two-faced effector in cancer and tumour suppression.

Rada M, Barlev N, Macip S.

Cell Death Dis. 2018 Oct 18;9(11):1064. doi: 10.1038/s41419-018-1122-8.

8.

BTK modulates p73 activity to induce apoptosis independently of p53.

Rada M, Barlev N, Macip S.

Cell Death Discov. 2018 Sep 11;4:30. doi: 10.1038/s41420-018-0097-7. eCollection 2018. Erratum in: Cell Death Discov. 2019 Jul 10;5:116.

9.

The biological basis and clinical symptoms of CAR-T therapy-associated toxicites.

Titov A, Petukhov A, Staliarova A, Motorin D, Bulatov E, Shuvalov O, Soond SM, Piacentini M, Melino G, Zaritskey A, Barlev NA.

Cell Death Dis. 2018 Sep 4;9(9):897. doi: 10.1038/s41419-018-0918-x.

10.

Effects of mycoplasma infection on the host organism response via p53/NF-κB signaling.

Borchsenius SN, Daks A, Fedorova O, Chernova O, Barlev NA.

J Cell Physiol. 2018 Jan;234(1):171-180. doi: 10.1002/jcp.26781. Epub 2018 Aug 26.

PMID:
30146800
11.

Novel isatin-derived molecules activate p53 via interference with Mdm2 to promote apoptosis.

Fedorova O, Daks A, Petrova V, Petukhov A, Lezina L, Shuvalov O, Davidovich P, Kriger D, Lomert E, Tentler D, Kartsev V, Uyanik B, Tribulovich V, Demidov O, Melino G, Barlev NA.

Cell Cycle. 2018;17(15):1917-1930. doi: 10.1080/15384101.2018.1506664. Epub 2018 Sep 5.

PMID:
30109812
12.

Combined treatment of human multiple myeloma cells with bortezomib and doxorubicin alters the interactome of 20S proteasomes.

Mittenberg AG, Kuzyk VO, Shabelnikov SV, Gorbach DP, Shatrova AN, Fedorova OA, Barlev NA.

Cell Cycle. 2018;17(14):1745-1756. doi: 10.1080/15384101.2018.1496742. Epub 2018 Aug 1.

13.

Specific Drug Delivery to Cancer Cells with Double-Imprinted Nanoparticles against Epidermal Growth Factor Receptor.

Canfarotta F, Lezina L, Guerreiro A, Czulak J, Petukhov A, Daks A, Smolinska-Kempisty K, Poma A, Piletsky S, Barlev NA.

Nano Lett. 2018 Aug 8;18(8):4641-4646. doi: 10.1021/acs.nanolett.7b03206. Epub 2018 Jul 9.

PMID:
29969563
14.

Ca2+ -depended signaling pathways regulate self-renewal and pluripotency of stem cells.

Ermakov A, Daks A, Fedorova O, Shuvalov O, Barlev NA.

Cell Biol Int. 2018 Sep;42(9):1086-1096. doi: 10.1002/cbin.10998. Epub 2018 Jun 19. Review.

PMID:
29851182
15.

TG2 regulates the heat-shock response by the post-translational modification of HSF1.

Rossin F, Villella VR, D'Eletto M, Farrace MG, Esposito S, Ferrari E, Monzani R, Occhigrossi L, Pagliarini V, Sette C, Cozza G, Barlev NA, Falasca L, Fimia GM, Kroemer G, Raia V, Maiuri L, Piacentini M.

EMBO Rep. 2018 Jul;19(7). pii: e45067. doi: 10.15252/embr.201745067. Epub 2018 May 11.

16.

Non-alcoholic fatty liver disease severity is modulated by transglutaminase type 2.

Piacentini M, Baiocchini A, Del Nonno F, Melino G, Barlev NA, Rossin F, D'Eletto M, Falasca L.

Cell Death Dis. 2018 Feb 15;9(3):257. doi: 10.1038/s41419-018-0292-8.

17.

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.

Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M, Candi E, Carmona-Gutierrez D, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Cohen GM, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D'Angiolella V, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, DeBerardinis RJ, Deshmukh M, Di Daniele N, Di Virgilio F, Dixit VM, Dixon SJ, Duckett CS, Dynlacht BD, El-Deiry WS, Elrod JW, Fimia GM, Fulda S, García-Sáez AJ, Garg AD, Garrido C, Gavathiotis E, Golstein P, Gottlieb E, Green DR, Greene LA, Gronemeyer H, Gross A, Hajnoczky G, Hardwick JM, Harris IS, Hengartner MO, Hetz C, Ichijo H, Jäättelä M, Joseph B, Jost PJ, Juin PP, Kaiser WJ, Karin M, Kaufmann T, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Knight RA, Kumar S, Lee SW, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lowe SW, Luedde T, Lugli E, MacFarlane M, Madeo F, Malewicz M, Malorni W, Manic G, Marine JC, Martin SJ, Martinou JC, Medema JP, Mehlen P, Meier P, Melino S, Miao EA, Molkentin JD, Moll UM, Muñoz-Pinedo C, Nagata S, Nuñez G, Oberst A, Oren M, Overholtzer M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pereira DM, Pervaiz S, Peter ME, Piacentini M, Pinton P, Prehn JHM, Puthalakath H, Rabinovich GA, Rehm M, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Ryan KM, Sayan E, Scorrano L, Shao F, Shi Y, Silke J, Simon HU, Sistigu A, Stockwell BR, Strasser A, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Thorburn A, Tsujimoto Y, Turk B, Vanden Berghe T, Vandenabeele P, Vander Heiden MG, Villunger A, Virgin HW, Vousden KH, Vucic D, Wagner EF, Walczak H, Wallach D, Wang Y, Wells JA, Wood W, Yuan J, Zakeri Z, Zhivotovsky B, Zitvogel L, Melino G, Kroemer G.

Cell Death Differ. 2018 Mar;25(3):486-541. doi: 10.1038/s41418-017-0012-4. Epub 2018 Jan 23. Review.

18.

BTK blocks the inhibitory effects of MDM2 on p53 activity.

Rada M, Althubiti M, Ekpenyong-Akiba AE, Lee KG, Lam KP, Fedorova O, Barlev NA, Macip S.

Oncotarget. 2017 Nov 20;8(63):106639-106647. doi: 10.18632/oncotarget.22543. eCollection 2017 Dec 5.

19.

Co-expression of RelA/p65 and ACTN4 induces apoptosis in non-small lung carcinoma cells.

Lomert E, Turoverova L, Kriger D, Aksenov ND, Nikotina AD, Petukhov A, Mittenberg AG, Panyushev NV, Khotin M, Volkov K, Barlev NA, Tentler D.

Cell Cycle. 2018;17(5):616-626. doi: 10.1080/15384101.2017.1417709. Epub 2018 Jan 22.

20.

Integrin-β4 is a novel transcriptional target of TAp73.

Xie N, Vikhreva P, Annicchiarico-Petruzzelli M, Amelio I, Barlev N, Knight RA, Melino G.

Cell Cycle. 2018;17(5):589-594. doi: 10.1080/15384101.2017.1403684. Epub 2018 Feb 8.

21.

Nutlin sensitizes lung carcinoma cells to interferon-alpha treatment in MDM2-dependent but p53-independent manner.

Shuvalov O, Kizenko A, Shakirova A, Fedorova O, Petukhov A, Aksenov N, Vasileva E, Daks A, Barlev N.

Biochem Biophys Res Commun. 2018 Jan 1;495(1):1233-1239. doi: 10.1016/j.bbrc.2017.11.118. Epub 2017 Nov 23.

PMID:
29175211
22.

Proapoptotic modification of substituted isoindolinones as MDM2-p53 inhibitors.

Grigoreva TA, Novikova DS, Petukhov AV, Gureev MA, Garabadzhiu AV, Melino G, Barlev NA, Tribulovich VG.

Bioorg Med Chem Lett. 2017 Dec 1;27(23):5197-5202. doi: 10.1016/j.bmcl.2017.10.049. Epub 2017 Oct 20.

PMID:
29089230
23.

E3 ubiquitin ligase Pirh2 enhances tumorigenic properties of human non-small cell lung carcinoma cells.

Daks A, Petukhov A, Fedorova O, Shuvalov O, Merkulov V, Vasileva E, Antonov A, Barlev NA.

Genes Cancer. 2016 Nov;7(11-12):383-393. doi: 10.18632/genesandcancer.123.

24.

One-carbon metabolism and nucleotide biosynthesis as attractive targets for anticancer therapy.

Shuvalov O, Petukhov A, Daks A, Fedorova O, Vasileva E, Barlev NA.

Oncotarget. 2017 Apr 4;8(14):23955-23977. doi: 10.18632/oncotarget.15053. Review.

25.

TUMOR MICROENVIRONMENT REGULATION BY HYPOXIA-INDICIBLE FACTORS (HIFs), AND p53 FAMILY PROTEINS.

Petrova VS, Barlev NA.

Tsitologiia. 2017;59(4):259-70. Review. English, Russian.

PMID:
30188089
26.

BTK Modulates p53 Activity to Enhance Apoptotic and Senescent Responses.

Althubiti M, Rada M, Samuel J, Escorsa JM, Najeeb H, Lee KG, Lam KP, Jones GD, Barlev NA, Macip S.

Cancer Res. 2016 Sep 15;76(18):5405-14. doi: 10.1158/0008-5472.CAN-16-0690. Epub 2016 Jul 26.

27.

Human EHMT2/G9a activates p53 through methylation-independent mechanism.

Rada M, Vasileva E, Lezina L, Marouco D, Antonov AV, Macip S, Melino G, Barlev NA.

Oncogene. 2017 Feb 16;36(7):922-932. doi: 10.1038/onc.2016.258. Epub 2016 Jul 25.

PMID:
27452519
28.

Extracellular Proteasomes Are Deficient in 19S Subunits as Revealed by iTRAQ Quantitative Proteomics.

Tsimokha AS, Zaykova JJ, Bottrill A, Barlev NA.

J Cell Physiol. 2017 Apr;232(4):842-851. doi: 10.1002/jcp.25492. Epub 2016 Aug 16.

PMID:
27430664
29.

Misrepresentation of the National Women's Hospital in Auckland, New Zealand.

Baird MA, Barlev N, Bryder L, Burls A, Carrell RW, Chalmers I, Cooper GJ, Dow DA, Hicks K, Keirse M, Mantell C, Nobbs P, Overton E, Overton H, Patten P, Sandercock J, Smith V, Trubuhovich R.

Am J Public Health. 2016 Jul;106(7):1208-9. doi: 10.2105/AJPH.2016.303162. No abstract available.

30.

Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy.

Clausse V, Goloudina AR, Uyanik B, Kochetkova EY, Richaud S, Fedorova OA, Hammann A, Bardou M, Barlev NA, Garrido C, Demidov ON.

Cell Death Dis. 2016 Apr 14;7:e2195. doi: 10.1038/cddis.2016.96.

31.

Regulation of Endoribonuclease Activity of Alpha-Type Proteasome Subunits in Proerythroleukemia K562 Upon Hemin-Induced Differentiation.

Mittenberg AG, Moiseeva TN, Kuzyk VO, Barlev NA.

Protein J. 2016 Feb;35(1):17-23. doi: 10.1007/s10930-015-9642-x.

PMID:
26661102
32.

KMT Set7/9 affects genotoxic stress response via the Mdm2 axis.

Lezina L, Aksenova V, Fedorova O, Malikova D, Shuvalov O, Antonov AV, Tentler D, Garabadgiu AV, Melino G, Barlev NA.

Oncotarget. 2015 Sep 22;6(28):25843-55. doi: 10.18632/oncotarget.4584.

33.

The 26S proteasome is a multifaceted target for anti-cancer therapies.

Grigoreva TA, Tribulovich VG, Garabadzhiu AV, Melino G, Barlev NA.

Oncotarget. 2015 Sep 22;6(28):24733-49. doi: 10.18632/oncotarget.4619. Review.

34.

Discovery of Novel Isatin-Based p53 Inducers.

Davidovich P, Aksenova V, Petrova V, Tentler D, Orlova D, Smirnov S, Gurzhiy V, Okorokov AL, Garabadzhiu A, Melino G, Barlev N, Tribulovich V.

ACS Med Chem Lett. 2015 Jul 6;6(8):856-60. doi: 10.1021/acsmedchemlett.5b00011. eCollection 2015 Aug 13.

35.

Current genome editing tools in gene therapy: new approaches to treat cancer.

Shuvalov O, Petukhov A, Daks A, Fedorova O, Ermakov A, Melino G, Barlev NA.

Curr Gene Ther. 2015;15(5):511-29. Review.

PMID:
26282844
36.

Genome-editing tools for stem cell biology.

Vasileva EA, Shuvalov OU, Garabadgiu AV, Melino G, Barlev NA.

Cell Death Dis. 2015 Jul 23;6:e1831. doi: 10.1038/cddis.2015.167. Review.

37.

[The role of mitochondrial dynamics in cell death].

Orlova DD, Tribulovich VG, Garabadzhiu AV, Barlev NA, Martin S.

Tsitologiia. 2015;57(3):184-91. Review. Russian.

PMID:
26021167
38.

TAp73 transcriptionally represses BNIP3 expression.

Petrova V, Mancini M, Agostini M, Knight RA, Annicchiarico-Petruzzelli M, Barlev NA, Melino G, Amelio I.

Cell Cycle. 2015 Aug 3;14(15):2484-93. doi: 10.1080/15384101.2015.1044178.

39.

Perspective on multi-target antiplatelet therapies: high content phenotypic screening as an unbiased source of novel polypharmacological strategies.

Landré V, Amelio I, Barlev NA, Knight RA, Lisitsa A, Melino G, Antonov AV.

Mini Rev Med Chem. 2015;15(8):622-9. Review.

PMID:
25930110
40.

[CRISPR/Cas system for genome editing in pluripotent stem cells].

Vasil'eva EA, Melino D, Barlev NA.

Tsitologiia. 2015;57(1):19-30. Review. Russian.

PMID:
25872372
41.

AMP-activated protein kinase: structure, function, and role in pathological processes.

Novikova DS, Garabadzhiu AV, Melino G, Barlev NA, Tribulovich VG.

Biochemistry (Mosc). 2015 Feb;80(2):127-44. doi: 10.1134/S0006297915020017. Review.

PMID:
25756529
42.

[THE USE OF THE COMMERCIAL APPARATUS DUAL GEL MODULE FOR THE TWO-DIMENSIONAL POLYACRYLAMIDE GEL ELECTROPHORESIS].

Evteeva IN, Starkova TY, Artemov AV, Barlev NA.

Tsitologiia. 2015;57(11):838-42. Russian.

PMID:
27012099
43.

[TUMOR SUPPRESSOR p63 REGULATES EXPRESSION OF UBIQUITIN LIGASE Pirh2].

Daks AA, Petukhov AV, Shuvalov OY, Vasilieva EA, Melino G, Barlev NA, Fedorova OA.

Tsitologiia. 2015;57(12):876-9. Russian.

PMID:
26995965
44.

[NEGATIVE REGULATORS OF TUMOR SUPPRESSOR P53 IN THE CONTEXT OF ANTICANCER THERAPY].

Shuvalov OY, Fedorova OA, Petukhov AV, Daks AA, Vasilieva EA, Grigorieva TA, Ivanov GS, Barlev NA.

Tsitologiia. 2015;57(12):847-54. Review. Russian.

PMID:
26995961
45.

[The use of apoptosis inducers in the therapy of experimental influenza infection and preventing of chronic post-influenza lung damage].

Zarubaev VV, Tribulovich VG, Beliavskaia SV, Barlev NA, Kiselev OI.

Tsitologiia. 2014;56(3):241-7. Russian.

PMID:
25509421
46.

[Design of cell line stable expressing proteasomal subunit PSMD14 fused to the fluorescent protein EGFP and HTBH tag based on HEK293 cells].

Kulichkova VA, Zaĭkova IuIa, Ermolaeva IuB, Vinogradova EV, Huang L, Tomilin AN, Barlev NA, Tsimokha AS.

Tsitologiia. 2014;56(3):218-24. Russian.

PMID:
25509418
47.

[Mass-spectrometric analysis of proteasomal subunits possessing endoribonuclease activity].

Mittenberg AG, Moiseeva TN, Kuzyk VO, Podol'skaia EP, Evteeva IN, Barlev NA.

Tsitologiia. 2014;56(4):300-15. Russian.

PMID:
25509164
48.

Characterization of novel markers of senescence and their prognostic potential in cancer.

Althubiti M, Lezina L, Carrera S, Jukes-Jones R, Giblett SM, Antonov A, Barlev N, Saldanha GS, Pritchard CA, Cain K, Macip S.

Cell Death Dis. 2014 Nov 20;5:e1528. doi: 10.1038/cddis.2014.489.

49.

Simultaneous EGFP and tag labeling of the β7 subunit for live imaging and affinity purification of functional human proteasomes.

Kulichkova VA, Artamonova TO, Zaykova JJ, Ermolaeva JB, Khodorkovskii MA, Barlev NA, Tomilin AN, Tsimokha AS.

Mol Biotechnol. 2015 Jan;57(1):36-44. doi: 10.1007/s12033-014-9799-0.

PMID:
25164490
50.

KMTase Set7/9 is a critical regulator of E2F1 activity upon genotoxic stress.

Lezina L, Aksenova V, Ivanova T, Purmessur N, Antonov AV, Tentler D, Fedorova O, Garabadgiu AV, Talianidis I, Melino G, Barlev NA.

Cell Death Differ. 2014 Dec;21(12):1889-99. doi: 10.1038/cdd.2014.108. Epub 2014 Aug 15.

Supplemental Content

Loading ...
Support Center